Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
5.47
-0.24 (-4.20%)
Aug 28, 2025, 4:00 PM - Market closed
Biodexa Pharmaceuticals Employees
Biodexa Pharmaceuticals had 13 employees as of December 31, 2024. The number of employees decreased by 8 or -38.10% compared to the previous year.
Employees
13
Change (1Y)
-8
Growth (1Y)
-38.10%
Revenue / Employee
n/a
Profits / Employee
-$551,714
Market Cap
3.39M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 13 | -8 | -38.10% |
Dec 31, 2023 | 21 | -6 | -22.22% |
Dec 31, 2022 | 27 | 7 | 35.00% |
Dec 31, 2021 | 20 | 2 | 11.11% |
Dec 31, 2020 | 18 | -47 | -72.31% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BDRX News
- 11 days ago - Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) - GlobeNewsWire
- 4 weeks ago - ADR Ratio Change Effective - GlobeNewsWire
- 4 weeks ago - How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market - Accesswire
- 6 weeks ago - ADR Ratio Change - GlobeNewsWire
- 6 weeks ago - Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) - GlobeNewsWire
- 2 months ago - Results of Annual General Meeting - GlobeNewsWire
- 2 months ago - Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) - GlobeNewsWire
- 2 months ago - Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) - GlobeNewsWire